KalVista Pharmaceuticals (KalVista Pharmaceuticals) Cash-to-Debt : 10.15 (As of Jan. 2024)

View and export this data going back to 2015. Start your Free Trial

What is KalVista Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. KalVista Pharmaceuticals's cash to debt ratio for the quarter that ended in Jan. 2024 was 10.15.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, KalVista Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Jan. 2024.

The historical rank and industry rank for KalVista Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

KALV' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.32 Med: 36.21 Max: No Debt
Current: 10.15

During the past 12 years, KalVista Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 0.32. And the median was 36.21.

KALV's Cash-to-Debt is ranked better than
56.27% of 1539 companies
in the Biotechnology industry
Industry Median: 6.49 vs KALV: 10.15

KalVista Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for KalVista Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

KalVista Pharmaceuticals Cash-to-Debt Chart

KalVista Pharmaceuticals Annual Data

Trend

Dec14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

41.16

42.13

20.30

18.15

KalVista Pharmaceuticals Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Cash-to-Debt	Get a 7-Day Free Trial															20.25	18.15	15.43	13.41	10.15

Competitive Comparison of KalVista Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, KalVista Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

KalVista Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, KalVista Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where KalVista Pharmaceuticals's Cash-to-Debt falls into.

KalVista Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

KalVista Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Apr. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	149.375	/	(1.087	+	7.145)
	=	18.15

KalVista Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Jan. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	75.586	/	(1.187	+	6.257)
	=	10.15

KalVista Pharmaceuticals (NAS:KALV) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

KalVista Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

KalVista Pharmaceuticals (KalVista Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (NAS:KALV) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

4XC1:Germany

Address

55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142

Website

https://www.kalvista.com

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.

Executives

Venrock Healthcare Capital Partners Iii, L.p.	10 percent owner	530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Edward P. Feener	officer: Chief Scientific Officer	ONE KENDALL SQUARE, BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139
Thomas Andrew Crockett	director, officer: President and CEO	BUILDING 227, TETRICUS SCIENCE PARK, PORTON DOWN, SALISBURY, WILTSHIRE X0 SP4 0JQ
Paul K. Audhya	officer: Chief Medical Officer	C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE MA 02142
Benjamin L Palleiko	officer: CFO and Secretary	C/O KALVISTA PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLD 200, STE 2203, CAMBRIDGE MA 02139
Christopher Yea	officer: Chief Development Officer	ONE KENDALL SQUARE, BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139
Albert Cha	director	505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Patrick Treanor	director	C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE MA 02142
Michael David Smith	officer: Senior VP, Development	C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE MA 02142
Andreas Maetzel	officer: Senior Vice President Medical	1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Nancy Stuart	director	99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421
Brian Jg Pereira	director	C/O ADVANCED MAGNETICS, INC., 61 MOONEY STREET, CAMBRIDGE MA 02138
Daniel B Soland	director	4560 HORTON STREET,M/S R-422, EMERYVILLE CA 94608
Martin Edwards	director	15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Sv Life Sciences Fund Iv (gp), L.p.	10 percent owner	ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108